These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15876265)

  • 1. Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre.
    Mulcahy R; Walsh M; Scully MF
    Haemophilia; 2005 May; 11(3):208-15. PubMed ID: 15876265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
    Bidlingmaier C; Deml MM; Kurnik K
    Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates.
    Dingli D; Gastineau DA; Gilchrist GS; Nichols WL; Wilke JL
    Haemophilia; 2002 Sep; 8(5):629-34. PubMed ID: 12199670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.
    Stieltjes N; Altisent C; Auerswald G; Négrier C; Pouzol P; Reynaud J; Roussel-Robert V; Savidge GF; Villar A; Schulman S
    Haemophilia; 2004 Sep; 10(5):452-8. PubMed ID: 15357770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience.
    Campbell PJ; Rickard KA
    Aust N Z J Med; 1998 Aug; 28(4):440-5. PubMed ID: 9777111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion in haemophilia: current practice in Europe.
    Batorova A; Holme P; Gringeri A; Richards M; Hermans C; Altisent C; Lopez-Fernández M; Fijnvandraat K;
    Haemophilia; 2012 Sep; 18(5):753-9. PubMed ID: 22530687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose continuous infusion of factor VIII in patients with haemophilia A.
    Prelog T; Dolničar MB; Kitanovski L
    Blood Transfus; 2016 Sep; 14(5):474-80. PubMed ID: 26674820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
    Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of factor prophylaxis in the Canadian haemophilia A population.
    Blanchette P; Rivard G; Israels S; Robinson S; Ali K; Walker I; Stain AM; Blanchette V;
    Haemophilia; 2004 Nov; 10(6):679-83. PubMed ID: 15569161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K; Walker I; Decker K; Chan AK; Pai MK
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A.
    Revel-Vilk S; Blanchette VS; Schmugge M; Clark DS; Lillicrap D; Rand ML
    Haemophilia; 2010 Jan; 16(1):72-9. PubMed ID: 19765092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: stability and clinical experience.
    O'Gorman P; Dimichele DM; Kasper CK; Mannucci PM; Santagostini E; Hay CR
    Haemophilia; 2001 Nov; 7(6):537-43. PubMed ID: 11851750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.